(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 27.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.65%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Ionis Pharmaceuticals's revenue in 2026 is $1,058,189,000.On average, 29 Wall Street analysts forecast IONS's revenue for 2026 to be $150,393,883,837, with the lowest IONS revenue forecast at $134,910,434,965, and the highest IONS revenue forecast at $164,328,822,559. On average, 28 Wall Street analysts forecast IONS's revenue for 2027 to be $256,652,749,468, with the lowest IONS revenue forecast at $198,976,117,424, and the highest IONS revenue forecast at $356,801,858,404.
In 2028, IONS is forecast to generate $366,882,874,320 in revenue, with the lowest revenue forecast at $286,895,797,216 and the highest revenue forecast at $534,954,893,772.